These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23436178)

  • 1. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
    Furuta S; Tamura M; Hirooka H; Mizuno Y; Miyoshi M; Furuta Y
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):87-96. PubMed ID: 23436178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.
    Furuta S; Smart C; Hackett A; Benning R; Warrington S
    Xenobiotica; 2013 May; 43(5):432-42. PubMed ID: 23075005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
    He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
    Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
    Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.
    Kato N; Oka M; Murase T; Yoshida M; Sakairi M; Yamashita S; Yasuda Y; Yoshikawa A; Hayashi Y; Makino M; Takeda M; Mirensha Y; Kakigami T
    Bioorg Med Chem; 2011 Dec; 19(23):7221-7. PubMed ID: 22019046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
    Goto M; Furuta S; Yamashita S; Hashimoto H; Yano W; Inoue N; Kato N; Kaku K
    J Diabetes Investig; 2018 Nov; 9(6):1261-1269. PubMed ID: 29754453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
    Ikedo T; Minami M; Kataoka H; Hayashi K; Nagata M; Fujikawa R; Higuchi S; Yasui M; Aoki T; Fukuda M; Yokode M; Miyamoto S
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28630262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation.
    Hotta Y; Takahashi S; Tokoro M; Naiki-Ito A; Maeda K; Kawata R; Kataoka T; Ohta Y; Hamakawa T; Takahashi S; Yasui T; Kimura K
    Neurourol Urodyn; 2020 Sep; 39(7):1922-1929. PubMed ID: 32725853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity.
    Yeh KC; Yeh TK; Huang CY; Hu CB; Wang MH; Huang YW; Chou LH; Ho HH; Song JS; Hsu T; Jiaang WT; Chao YS; Chen CT
    Life Sci; 2021 Aug; 278():119574. PubMed ID: 33961850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
    Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall.
    Li Q; Zhang M; Xuan L; Liu Y; Chen C
    Free Radic Biol Med; 2018 Jun; 121():105-116. PubMed ID: 29715547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
    Fuchs H; Runge F; Held HD
    Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.